Scott Johnson - EXACT Sciences Senior Vice President Research & Development

EXAS Stock  USD 60.22  0.21  0.35%   

President

Mr. Scott Johnson is Senior Vice President, Research Development of the Company. He has served as our Senior Vice President, Research Development since September 2017. He joined us from Luminex Corporationrationration, a molecular diagnostic product and life sciences tools manufacturer, where he served as Vice PresidentAssay Research Development from 2014 to 2017 and as Vice PresidentProduct Development Manufacturing from 2011 to 2014. Prior to EraGen Biosciences acquisition by Luminex, Dr. Johnson served as EraGen Biosciences Vice PresidentProduct from 2008 to 2011 since 2017.
Age 49
Tenure 7 years
Professional MarksMBA
Address 5505 Endeavor Lane, Madison, WI, United States, 53719
Phone608 284 5700
Webhttps://www.exactsciences.com
Johnson earned a bachelor degree in biotechnology from Rochester Institute of Technology, a doctorate in cellular and molecular biology from University of Wisconsin—Madison and an MBA from the Kellogg Graduate School of Management at Northwestern University.

EXACT Sciences Management Efficiency

The company has return on total asset (ROA) of (0.0304) % which means that it has lost $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Debt To Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.41 in 2024, whereas Return On Tangible Assets are likely to drop (0.1) in 2024.
The company currently holds 2.55 B in liabilities with Debt to Equity (D/E) ratio of 0.77, which is about average as compared to similar companies. EXACT Sciences has a current ratio of 2.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist EXACT Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, EXACT Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EXACT Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EXACT to invest in growth at high rates of return. When we think about EXACT Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Omead OstadanIllumina
46
Brian EllisDanaher
57
Richard MarshMyriad Genetics
59
Marcel RocheGuardant Health
N/A
Mark StevensonThermo Fisher Scientific
57
William KingDanaher
53
Daniel RaskasDanaher
54
Andrew ThomsonThermo Fisher Scientific
49
Angela LalorDanaher
59
Ralph McDadeMyriad Genetics
62
Reginald SeetoCaredx Inc
52
Patrick WeissTwist Bioscience Corp
48
James DitkoffDanaher
67
Stephen WilliamsonThermo Fisher Scientific
57
Daniel ComasDanaher
55
Samraat RahaAgilent Technologies
51
Michael TangAgilent Technologies
50
Peter HornstraThermo Fisher Scientific
59
Jacob ThaysenAgilent Technologies
49
Patrick KaltenbachAgilent Technologies
53
Michael BoxerThermo Fisher Scientific
58
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people. EXACT Sciences (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane, Madison, WI, United States, 53719 and employs 6,500 people. EXACT Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

EXACT Sciences Leadership Team

Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Katherine Napier, Independent Director
Sally Crawford, Independent Director
Jeffrey Elliott, CFO
Kevin Conroy, Chairman of The Board, CEO and Pres
James Doyle, Independent Director
Ana Hooker, Senior Vice President Operations
Thomas Carey, Independent Director
John Fallon, Director
Scott Johnson, Senior Vice President Research & Development
Daniel Levangie, Independent Director
Vic Parker, Head Sales
John Bakewell, CFO
Sri Kalluri, Chief Officer
Nassar Nizami, Chief Officer
William Megan, Principal Financial Officer and Sr. VP of Fin.
Scott Coward, Sr. VP and General Counsel
Pierre Jacquet, Director
Graham Lidgard, Chief Science Officer and Sr. VP
Jorge Garces, Chief Officer
Jeffrey CFA, Chief Officer
David Thompson, Lead Independent Director
Michael Wyzga, Director
Lionel Sterling, Independent Director
James Herriott, General VP
Andrew Slavitt, Director
Sarah Condella, Executive Resources
Mark Stenhouse, President Cologuard
Tim Caprez, Chief VP
Kathleen Sebelius, Director
Everett Cunningham, Chief Officer
Maneesh Arora, COO, Sr. VP and Director
Katherine Zanotti, Independent Director
Eli Casdin, Independent Director
Megan Jones, Associate Relations

EXACT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with EXACT Sciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EXACT Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EXACT Sciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with EXACT Stock

  0.72DYAI Dyadic International Financial Report 8th of May 2024 PairCorr

Moving against EXACT Stock

  0.63LFCR Lifecore Biomedical Financial Report 6th of June 2024 PairCorr
  0.58HOWL Werewolf Therapeutics Earnings Call This WeekPairCorr
  0.56MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.41IKNA Ikena Oncology Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to EXACT Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EXACT Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EXACT Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EXACT Sciences to buy it.
The correlation of EXACT Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EXACT Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EXACT Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EXACT Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether EXACT Sciences is a strong investment it is important to analyze EXACT Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact EXACT Sciences' future performance. For an informed investment choice regarding EXACT Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.
Note that the EXACT Sciences information on this page should be used as a complementary analysis to other EXACT Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for EXACT Stock analysis

When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is EXACT Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXACT Sciences. If investors know EXACT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.13)
Revenue Per Share
13.876
Quarterly Revenue Growth
0.17
Return On Assets
(0.03)
Return On Equity
(0.07)
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EXACT Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if EXACT Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EXACT Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.